ConductScience.org, home

Paper34012000

Double setback for ASO trials in Huntington disease.

Kingwell K. Nat Rev Drug Discov, 2021. Cited by 91 papers, by iCite.

Cite this record

ConductScience Library. Double setback for ASO trials in Huntington disease. Papers, record 34012000. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34012000

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Double setback for ASO trials in Huntington disease.
PubMed
Journal
Nat Rev Drug Discov
PubMed
Year
2021
PubMed
Publication types
News
PubMed
Citations, by iCite
91
iCite
Relative citation ratio, by iCite
4.88
iCite
Revised in PubMed
2021-08-10
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kingwell KKatie

Source PubMed

Download CSV of authors

Topics5

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Huntingtin ProteinMajor topic
Huntington DiseaseMajor topic
Oligonucleotides, AntisenseMajor topic
Humans
Treatment Failure

Cited by68

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 91 citations.

PMIDTitleJournalYearIn PapersSource
42714706Evaluation of curcumin as an exploratory pharmacological tool for modulating dysregulated molecular pathways in cellular models of Huntington's disease.Mol Biol Rep2026https://conductscience.org/library/papers/42714706PubMed
42549268Enhancing the detection of HTT1a with neoepitope antibodies in mouse models of Huntington's disease.Brain Commun2026https://conductscience.org/library/papers/42549268PubMed
42181874An integrative neuropharmacological review of Huntington's disease challenges and the role of novel formulations in addressing pharmacological‒pharmaceutical limitations.Front Pharmacol2026https://conductscience.org/library/papers/42181874PubMed
42091595Double strand breaks drive toxicity in a Huntington's disease mouse model with or without somatic expansion.Nat Commun2026https://conductscience.org/library/papers/42091595PubMed
41622913The HTT1a protein initiates HTT aggregation in a knock-in mouse model of Huntington's disease.Brain2026https://conductscience.org/library/papers/41622913PubMed
41422503Repeat-associated non-AUG translation as a common mechanism for the polyGln ataxias.Cell Rep2026https://conductscience.org/library/papers/41422503PubMed
41213972Development of a targeted BioPROTAC degrader selective for misfolded SOD1.Nat Commun2025https://conductscience.org/library/papers/41213972PubMed
41090155Gene and RNA Editing: Revolutionary Approaches to Treating Diseases.MedComm (2020)2025https://conductscience.org/library/papers/41090155PubMed
40676294Natural products proposed for the management of Huntington's disease (HD): a comprehensive review.Naunyn Schmiedebergs Arch Pharmacol2025https://conductscience.org/library/papers/40676294PubMed
40656227Prospects for improved prevention and treatment of neuropsychiatric disorders: Neuroscience Applied.Neurosci Appl2022https://conductscience.org/library/papers/40656227PubMed
40574039In Vitro Efficacy of PEI-Derived Lipopolymers in Silencing of Toxic Proteins in a Neuronal Model of Huntington's Disease.Pharmaceutics2025https://conductscience.org/library/papers/40574039PubMed
40501854Double strand breaks drive toxicity in Huntington's disease mice with or without somatic expansion.bioRxiv2025https://conductscience.org/library/papers/40501854PubMed
40499536The cell-surface shared proteome of astrocytes and neurons and the molecular foundations of their multicellular interactions.Neuron2025https://conductscience.org/library/papers/40499536PubMed
40455873The parasagittal dural space of the human brain.Brain2025https://conductscience.org/library/papers/40455873PubMed
40234398Inhibitor-based modulation of huntingtin aggregation mechanisms mitigates fibril-induced cellular stress.Nat Commun2025https://conductscience.org/library/papers/40234398PubMed
40102650Errors in the Huntington's disease gene accumulate slowly and then all at once.Nature2025https://conductscience.org/library/papers/40102650PubMed
39881338Molecular and cellular characteristics of cerebrovascular cell types and their contribution to neurodegenerative diseases.Mol Neurodegener2025https://conductscience.org/library/papers/39881338PubMed
39862873Crossing the blood-brain barrier: emerging therapeutic strategies for neurological disease.Lancet Neurol2025https://conductscience.org/library/papers/39862873PubMed
39824182Long somatic DNA-repeat expansion drives neurodegeneration in Huntington's disease.Cell2025https://conductscience.org/library/papers/39824182PubMed
39789319RNA dysregulation in neurodegenerative diseases.EMBO J2025https://conductscience.org/library/papers/39789319PubMed

See all 68 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/34012000

GET https://conductscience.org/api/papers/v1/34012000/cited_by?page=2